Vaccine therapy in non-small-cell lung cancer

Current Oncology Reports

Volumn 9, Issue 4, 2007, Pages 241-246

  Albright, Carol ^a   Garst, Jennifer ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BELAGENPUMATUCEL L; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; MELANOMA ANTIGEN 3; MUCIN 1; RECOMBINANT DNA; RNA BINDING PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE OF DEATH; CELL BASED GENE THERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; LUNG SURGERY; PROGNOSIS; REVIEW; TUMOR CELL LINE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DENDRITIC CELLS; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS; NEOPLASM PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 34447272914     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0029-9     Document Type: Review

References (39)

1. National Cancer Institute. Available at http://www.cancer.gov/ cancertopics/types/lung. Accessed February 2007.
2. Travis WD, Colby TV, Corrin B, et al.: Histological Typing of Lung and Pleural Tumours, edn 3. Berlin: Springer-Verlag; 1999.
3. Cranmer LD, Trevor KT, Hersh EM: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004, 53:275-306.
4. Chang GC, Lan HC, Juang SH, et al.: A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 2005, 103:763-771.
5. Hirschowitz EA, Foody T, Kryscio R, et al.: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004, 22:2808-2815.
6. Yannelli JR, Sturgill J, Foody T, et al.: The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2005, 47:337-350.
7. Hammarstrom S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67-81.
8. Itoh T, Ueda Y, Kawashima I, et al.: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002, 51:99-106.
9. Ueda Y, Itoh T, Nukaya I, et al.: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004, 24:909-917.
10. Morse MA, Clay TM, Hobeika AC, et al.: Phase I study of immunization with dendritic cells modified with Fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005, 11:3017-3024.
11. Rusch V, Baselga J, Cordon-Cardo C, et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-2385.
12. Gonzalez G, Crombet T, Catala M, et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 1998, 9:431-35.
13. Gonzalez G, Crombet T, Torres F, et al.: Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003, 14:461-466.
14. Ramos TC, Vinageras EN, Ferrer MC, et al.: Treatment of NSCLC patients with and EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006, 5:145-149.
15. Uchida N, Otsuka T, Shigematsu H, et al.: Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 1999, 23:1127-1132.
16. Tahara H, Yasui W, Tahara E, et al.: Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumour and non-tumour tissue sections. Oncogene 1999, 18:1561-1567.
17. Fujita Y, Fujikane T, Fujiuchi S, et al.: The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non-small cell lung carcinoma. Cancer 2003, 298:1008-1013.
18. Brunsvig PF, Aamdal S, Gjertsen MK, et al.: Telomerase peptide vaccination: a phase I/TI study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55:1553-1564.
19. Kotani K, Taguchi O, Narita T, et al.: Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001, 84:1258-1264.
20. Rochlitz C, Figlin R, Squiban P, et al.: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003, 5:690-699.
21. Kontani K, Taguchi O, Ozaki Y, et al.: Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003, 12:493-502.
22. Palmer M, Parker J, Modi S, et al.: Phase I study of the BLP25 (MUC1 peptide) lisosomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2001, 3:49-57.
23. Butts C, Murray N, Maksymiuk A, et al.: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23: 6674-6681.
24. Van den Eynde BJ, van der Bruggen P: T cell defined tumour antigens. Curr Opin Immunol 1997, 9:684-693.
25. Atanackovic D, Altorki NKI, Stockert E, et al.: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004, 172:3289-3296.
26. Denzer K, Kleijmeer MJ, Heijnen HF, et al.: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113:3365-3374.
27. Thery C, Duban L, Segura E, et al.: Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002, 3:1156-1162.
28. Andre F, Chaput N, Schartz, NEC, et al.: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004, 172:2126-2136.
29. Morse MA, Garst J, Osada T, et al.: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9-16.
30. Mueller-Pillasch F, Pohl B, Wilda M, et al.: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95-99.
31. Nemunaitis J, Meyers T, Senzer N, et al.: Phase I trial of sequential administration of recombinant DNA and adenoviral expressing L523S protein in early stage non small cell lung cancer (NSCLC). Mol Ther 2006, 13:1185-1191.
32. Raez LE, Cassileth PA, Schlessetman JJ, et al.: Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:2800-2807.
33. Scheffer SR, Nave H, Korangy F, et al.: Apoptotic but not necrotic tumour cell vaccines induce a potent, specific, and long-lasting antitumour immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
34. Salgia R, Lynch T, Skarin A, et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulation factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003, 21:624-630.
35. Nemunaitis J, Sterman D, Jablons D, et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:326-331.
36. Nemunaitis J, Jahan T, Ross H, et al.: Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006, 13:555-562.
37. Jakowlew SB, Mathias A, Chung P, et al.: Expression of transforming growth factor beta tigand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995, 6:465-476.
38. Kong F, Jirtle RL, Huang DH, et al.: Plasma transforming growth factor-beta1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer 1999, 86:1712-1719.
39. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al.: Phase II study of Belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730.